Abpro Corporation, a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; and ABP-201 for the treatment of vascular diseases of the eye. Abpro Corporation has a collaboration and license agreement with Essex Bio-Investment Ltd., AbMed Corporation, MedImmune Ltd., and Luye Pharma Group Ltd.; and license agreement with Memorial Sloan Kettering Cancer Center and National Cancer Institute. The company was formerly known as IE LAB, Inc. and changed its name to Abpro Corporation in September 2007. Abpro Corporation was founded in 2004 and is headquartered in Woburn, Massachusetts.